The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $135.80

Today's change-1.73 -1.26%
Updated May 25 1:14 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $135.80

Today's change-1.73 -1.26%
Updated May 25 1:14 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd down (U.S.)$1.73

Taro Pharmaceutical Industries Ltd is lower today, dropping (U.S.)$1.73 or 1.26% to (U.S.)$135.80. Over the last five days, shares have lost 0.66% and are down 12.13% for the last year to date. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $137.50
  • Previous close(U.S.) $137.53
  • High(U.S.) $137.50
  • Low(U.S.) $135.58
  • Bid / Ask(U.S.) $135.80 / (U.S.) $135.99
  • YTD % change-12.13%
  • Volume71,064
  • Average volume (10-day)239,487
  • Average volume (1-month)218,253
  • Average volume (3-month)145,830
  • 52-week range(U.S.) $122.99 to (U.S.) $157.99
  • Beta0.87
  • Trailing P/E9.64×
  • P/E 1 year forward11.54×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $14.09
Updated May 25 1:14 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+62.28%

Based on its net profit margin of 62.28%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.93%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue258212215244
Total other revenue--------
Total revenue258212215244
Gross profit214169172200
Total cost of revenue44434345
Total operating expense85878191
Selling / general / administrative23242322
Research & development18191524
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0100
Other operating expenses, total--------
Operating income173125134154
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax201164134190
Income after tax189134104153
Income tax, total12303037
Net income189133104152
Total adjustments to net income--------
Net income before extra. items189133104153
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items189133104153
Inc. avail. to common incl. extra. items189133104152
Diluted net income189133104152
Dilution adjustment--------
Diluted weighted average shares43434337
Diluted EPS excluding extraordinary itemsvalue per share4.413.112.424.14
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share4.413.132.424.14